Shanghai Henlius Biotech, Inc. has made a public announcement that the NMPA has given approval to the NDA for an innovative fresh indication of HANSIZHUANG (serplulimab injection).

This article summarized the latest R&D progress of Doxepin Hydrochloride, the Mechanism of Action for Doxepin Hydrochloride, and the drug target R&D trends for Doxepin Hydrochloride.

PRMT5 expression is associated with a poor prognosis in tumor progression and metastasis.

This article summarized the latest R&D progress of Torsemide, the Mechanism of Action for Torsemide, and the drug target R&D trends for Torsemide.

SELLAS reveals uplifting preliminary findings in Lymphoma group from SLS009 Phase 1 Increasing-Dose Study, promoting progression to Phase 2 Clinical Experiment.

This article summarized the latest R&D progress of Nabumetone, the Mechanism of Action for Nabumetone, and the drug target R&D trends for Nabumetone.

PARP1 is the most prominent member of the PARP family, accounting for 80%-90% of the enzyme activity, and is a key player in DNA damage repair.

This article summarized the latest R&D progress of Thiocolchicoside, the Mechanism of Action for Thiocolchicoside, and the drug target R&D trends for Thiocolchicoside.

Krystal Biotech publicized that the U.S. FDA has given the green light for the Investigational New Drug application for KB408 to manage alpha-1 antitrypsin deficiency.

This article summarized the latest R&D progress of Tianeptine Sodium, the Mechanism of Action for Tianeptine Sodium, and the drug target R&D trends for Tianeptine Sodium.

Programmed death-ligand 1 (PD-L1) is a protein found on the surface of certain cells in the human body, including immune cells and some cancer cells.

This article summarized the latest R&D progress of Tibolone, the Mechanism of Action for Tibolone, and the drug target R&D trends for Tibolone.